Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010

Clinical Research in Cardiology

Volumn 100, Issue 1, 2011, Pages 1-9

  Gensch, Christoph ^a   Hoppe, Uta ^a,b   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

ACT; ADVANCE; ASCEND HF; ASCOT CRP; CLOSURE I; DEFINE; EMPHASIS HF; GRAVITAS; P OM3; RAFT; ROCKET AF; SMART AV; SYMPLICITY HTN 2; TELE HF; TIM HF

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANACETRAPIB; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOPIDOGREL; CREATININE; DABIGATRAN; EPLERENONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NESIRITIDE; OMEGA 3 FATTY ACID; PLACEBO; RIVAROXABAN; ROSUVASTATIN; WARFARIN;

ANGIOGRAPHY; ARTICLE; BRAIN HEMORRHAGE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DEFIBRILLATOR; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; HEALTH STATUS; HEART ASSIST DEVICE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART TRANSPLANTATION; HOSPITAL READMISSION; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; KIDNEY DENERVATION; LOADING DRUG DOSE; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; STENT THROMBOSIS; SYSTOLIC HEART FAILURE; TELEMONITORING; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

BIOMEDICAL RESEARCH; CARDIOLOGY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; UNITED STATES;

EID: 79551534844     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0270-3     Document Type: Article

References (32)

1. U Laufs H Nef H Möllmann F Custodis M Böhm 2008 Clinical trial updates and hotline sessions presented at the Scientific Session 2007 of the American Heart Association Clin Res Cardiol 97 1 1 11 1:STN:280: DC%2BD1c%2FjvFyrsw%3D%3D 10.1007/s00392-008-0625-1 18075766
2. H Möllmann H Nef M Böhm U Laufs 2009 Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association Clin Res Cardiol 98 1 1 7 10.1007/s00392-008-0742-x 19083039
3. Berwanger O (2010) Acetylcystein for the prevention of contrast-induced nephropathy (ACT) trial: a pragmatic multicenter randomized trial to evaluate the efficacy of acetylcysteine for the prevention of renal outcomes in patients undergoing coronary and vascular angiography. American Heart Association Scientific Sessions, November 16 2010, Chicago, IL (Late Breaking Clinical Trials III)
4. Aaronson KD (2010) Evaluation of the HeartWare® HVAD left ventricular assist device system for bridge to tranaplant in advanced heart failure: the ADVANCE trial. American Heart Association 2010 Scientific Sessions; November 15, Chicago, IL. Late-Breaking Clinical Trials I
5. Hernandez AF (2010) Acute study of clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF)-nesiritide or placebo for improved symptoms and outcomes in acute decompensated HF. American Heart Association 2010 Scientific Sessions, November 14 2010, Chicago, IL (Late-Breaking Clinical Trials I)
6. Sever P (2010) The anglo-scandinavian cardiac outcomes trial (ASCOT): testing C-reactive protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes. American Heart Association 2010 Scientific Sessions, November 17 2010, Chicago, IL (Late breaking clinical trials IV)
7. PM Ridker E Danielson FA Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein New Engl J Med 359 2195 2207 1:CAS:528:DC%2BD1cXhtl2gurnL 10.1056/NEJMoa0807646 18997196
8. Furlan A (2010) CLOSURE I: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFLEX® septal closure system versus best medical therapy in patients with a stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. American Heart Association 2010 Scientific Sessions; November 15 2010, Chicago, IL (Late-breaking clinical trials II)
9. Cannon CP, Shah S, Hayes MD et al (2010) Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. doi: 10.1056/NEJMoa1009744
10. Cannon CP (2010) Primary results of the DEFINE trial: determining the efficacy and tolerability of CETP inhibition with anacetrapid. American Heart Association 2010 Scientific Sessions, November 17 2010, Chicago, IL (Late-breaking clinical trials IV)
11. J Pöss M Böhm U Laufs 2010 HDL im Rahmen der Atherogenese und HDL-Steigerung durch CETP-Inhibition Dtsch Med Wochenschr 135 188 192 10.1055/s-0030-1247862 20082258
12. Zannad F (2010) The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure. EMPhASIS-HF. American Heart Association 2010 Scientific Sessions, November 14 2010, Chicago, IL (Late-breaking clinical trials I)
13. Zannad F, McMurray JJ, Krum H et al (2010) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. doi 10.1056/ NEJMoa1009492
14. MJ Price PB Berger, et al. 2009 Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial Am Heart J 157 5 818 824 1:CAS:528:DC%2BD1MXkslGns78%3D 10.1016/j.ahj.2009.02.012 19376306
15. Price MJ (2010) Standard versus high-dose clopidogrel according to platelet function testing after PCI: results of the GRAVITAS trial. American Heart Association 2010 Scientific Sessions, November 16 2010, Chicago, IL (Late-breaking clinical trials III)
16. Kowey PR, Reiffel JA, Ellenbogen KA et al (2010) Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation. A randomized controlled trial. JAMA. doi: 10.1001/jama.2010.1735
17. Kowey PR (2010) Efficacy and safety of prescription omega-3-acid ethyl esters (P-OM3) for the prevention of recurrent symptomatic atrial fibrillation (AF). American Heart Association 2010 Scientific Sessions, November 15 2010, Chicago, IL (Late-breaking clinical trials II)
18. Tang AS, Wells GA, Talajic M et al (2010) Cardiac-Resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. doi 10.1056/NEJMoa1009540
19. Tang AS (2010) The resynchronization/defibrillation for ambulatory heart failure trial (RAFT). American Heart Association 2010 Scientific Sessions, November 14, Chicago, IL. (Late-breaking clinical trials I)
20. Mahaffey K (2010) Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). American Heart Association 2010 Scientific Sessions, November 15 2010, Chicago, IL (Late-breaking clinical trials II)
21. SJ Connolly MD Ezekowitz S Yusuf, et al. 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 1151 1:CAS:528:DC%2BD1MXhtFOjsLnN 10.1056/NEJMoa0905561 19717844
22. Ellenbogen K, Gold M, Meyer T (2010) Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial. Circulation. doi: 10.1161/CIRCULATIONAHA.110.992552
23. Ellenbogen K (2010) Primary results from the SMART-AV trial: a randomized trial comparing empiric, echocardiographic guided and algorithmic AV delay programming in cardiac resynchronization therapy (CRT). American Heart Association 2010 Scientific Sessions, November 15 2010, Chicago, IL (Late-breaking clinical trials II)
24. D Lloyd-Jones RJ Adams TM Brown, et al. 2010 Heart disease and stroke statistics-2010 update: a report from the American Heart Association Circulation 121 e46 e215 10.1161/CIRCULATIONAHA.109.192667 20019324
25. K Wolf-Maier RS Cooper H Kramer, et al. 2004 Hypertension treatment and control in five European countries, Canada and the United States Hypertension 43 10 17 1:CAS:528:DC%2BD3sXpvVeqtr8%3D 10.1161/01.HYP.0000103630.72812.10 14638619 (Pubitemid 38031904)
26. GF DiBona UC Kopp 1997 Neural control of renal function Physiol Rev 77 75 197 1:CAS:528:DyaK2sXhvVeqsrc%3D 9016301
27. Krum H et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671):1275-1281 epub 2009 Mar 28
28. Symplicity HTN-2 Investigators (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. doi: 10.1016/S0140-6736(10)62039-9
29. Esler M (2010) SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. American Heart Association 2010 Scientific Sessions, November 17 2010, Chicago, IL (Late-breaking clinical trials IV)
30. Chaudhry SI, Mattera JA, Curtis JP et al (2010) Telemonitoring in patients with heart failure. N Engl J Med. doi: 10.1056/NEJMoa1010029
31. Chaudhry SI (2010) Telemonitoring to improve outcomes after heart failure hospitalization: a randomized clinical trial. American Heart Association 2010 Scientific Sessions, November 16 2010, Chicago, IL (Clinical science: special reports III)
32. Anker SD (2010) Telemedical interventional monitoring in heart failure (TIM-HF), a randomized, controlled, intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with chronic heart failure. American Heart Association 2010 Scientific Sessions, November 16 2010, Chicago, IL (Clinical science: special reports III)